Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel echinococosis granulosis vaccine with CPG DNA (deoxyribonucleic acid) immune adjuvants

A hydatid and vaccine technology, applied in the field of vaccine development, can solve problems affecting meat quality, safety concerns, granulation, etc., and achieve good effects of cellular immunity and humoral immunity

Inactive Publication Date: 2016-01-27
BEIJING ZHONGNONG BIOLOGICAL ENG CO LTD
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But it is also accompanied by certain side effects, especially epithelial macrophage granulation and ulceration at the injection site
In addition, mineral oil cannot be metabolized, so it exists in the tissue for a long time, affecting the quality of meat, causing livestock breeders to worry about the safety of this type of mineral oil adjuvant
Mineral oil is a mixture of various saturated hydrocarbons. The greater the relative molecular weight of alkanes, the less toxic they are, but the less obvious the adjuvant effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel echinococosis granulosis vaccine with CPG DNA (deoxyribonucleic acid) immune adjuvants
  • Novel echinococosis granulosis vaccine with CPG DNA (deoxyribonucleic acid) immune adjuvants
  • Novel echinococosis granulosis vaccine with CPG DNA (deoxyribonucleic acid) immune adjuvants

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The construction of embodiment 1 recombinant plasmid PET-EG95S

[0037] 1.1 Activation and emulsification of hydatid eggs

[0038] The aseptically treated hydatid eggs were washed and incubated and activated according to the method of Heath and Lawrence. Four million activated hydatid cells were incubated for 14 days in 40 ml of NCTC (Gibco) medium containing 260 mg / l L-cysteine ​​and 20% lamb serum. During this period, the medium was changed every two days, and all culture media were filtered through a 0.22 μm filter membrane and stored at 4°C. After the cultivation, the culture solution was concentrated to 20 ml by dialysis and stored at -20°C.

[0039] 1.2 Preparation of total RNA

[0040] About 4×10 6 After the mature hydatid eggs were activated in vitro, the total RNA was extracted according to the instructions of the total RNA extraction kit (Total RNA Isolation System).

[0041] (1) When extracting tissue RNA, use 1ml Trizol reagent for every 50-100mg tissue...

Embodiment 2

[0089] Expression, purification and identification of embodiment 2 recombinant protein

[0090] 2.1 Induced expression and purification of recombinant protein

[0091] The recombinant plasmid PET-EG95s prepared in Example 1 was respectively transformed into E.coliBL21 (DE3) competent cells, and a single colony was picked and inoculated into 10 mL of LB medium containing ampicillin at a final concentration of 25 μg / ml, at 37°C 200r / Shake culture overnight, inoculate 1ml of the culture into 100ml LB medium containing ampicillin at a final concentration of 25μg / ml, and culture with shaking at 200r / min at 37°C until OD 600 When nm=0.6, add IPTG with a final concentration of 1 mM, and culture at 22° C. with shaking at 160 rpm for 10 h. Collect the bacteria by centrifugation at 6000r / min for 10min, wash twice with 40mL PBS (pH7.4), resuspend in 10mlPBS (pH7.4), break the bacteria by ultrasonication in an ice bath, centrifuge the broken mixture at 12000rpm, 4℃ for 30min, and take i...

Embodiment 3

[0097] The preparation of embodiment 3 novel echinococcus vaccines

[0098] 3.1 Quantification of recombinant protein EG95s protein

[0099] After the endotoxin-free EG95s recombinant protein prepared in 2.2 was quantified by the BCA protein concentration detection kit, SDS-PAGE electrophoresis was performed, and the percentage of the target protein EG95s in the total protein was analyzed by Bandscan5.0 software, and the target protein content was finally calculated.

[0100] 3.3 Preparation of the vaccine

[0101] Eg95s: directly filter the quantified EG95s antigen through a 0.22μm filter, dilute it with PBS to contain 50μg / ml EG95s antigen per head, 1.0ml per head, pack in 100ml bottles, 50 heads per bottle, use sterile gel Plug it in and make a record.

[0102] Eg95s+QuilA: Mix 1.0ml per head, containing 1mgQuilA and 50μg EG95s antigen, filter through a 0.22μm filter, and vortex to mix. The prepared vaccine is divided into 100 ml bottles, 50 doses per bottle, covered wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of vaccine development, and provides novel echinococosis granulosis vaccine for preventing intermediate hosts of echinococosis for human, livestock and the like. The novel echinococosis granulosis vaccine comprises soluble expression mixtures of Eg95 recombinant proteins, aluminum hydroxide and CpG immune adjuvants. The novel echinococosis granulosis vaccine has the advantage that excellent cellular immunity and humoral immunity of bodies can be effectively stimulated by the novel echinococosis granulosis vaccine.

Description

technical field [0001] The invention belongs to the technical field of vaccine development. The invention relates to the development of echinococcus vaccine and the screening and preparation of immune adjuvant. Background technique [0002] Echinococcus granulosis, also known as hydatidosis, is a disease caused by the middle stage of Echinococcus parasitic in the small intestine of dogs, wolves, foxes and other animals—the intermediate host infected by Echinococcus. Seriously harmful chronic zoonosis, can infect livestock such as sheep, cattle, pigs, camels and horses, as well as various wild animals and humans, parasitize the liver, lungs and other organs to produce space-occupying lesions, cystic echinococcosis The sudden rupture of the lesion can cause anaphylactic shock and death, which will cause serious public health problems and bring huge losses to animal husbandry production. It has been listed as a legally reportable animal disease by the World Organization for A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K39/39A61K39/00A61P33/10C12N15/70
Inventor 朱西洲吴竞
Owner BEIJING ZHONGNONG BIOLOGICAL ENG CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com